logo-loader
RNS
Redx Pharma PLC

Redx Pharma plc - Share Purchases by PDMR’s

RNS Number : 4972M
Redx Pharma plc
30 April 2024
 

REDX PHARMA PLC

 

("Redx" or the "Company")

 

Share Purchases by PDMR's


Alderley Park, UK, 30 April 2024 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, targeted therapeutics for the treatment of fibrotic disease and cancer today announces that it has been notified that Peter Collum, Chief Financial Officer and Claire Solk, General Counsel, both of whom are classed as persons discharging managerial responsibility ("PDMR's") under EU Regulation 596/2014 as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 have on 26 and 29 April 2024 acquired 267,108 Redx ordinary shares as follows:

 

Name

Position

Shares purchased

Weighted average price

Total shares held following the purchase

% of the issued share capital

Peter Collum

Chief Financial Officer

95,000

10.08p

95,000

0.02%

Claire Solk

General Counsel

172,108

11.74p

172,108

0.04%

 

Further information on the purchase is contained within the disclosure tables below.

 

 

For further information, please contact:






Redx Pharma Plc

UK Headquarters

Caitlin Pearson, Head of Communications 

ir@redxpharma.com

 

T: +44 (0)1625 469 918

SPARK Advisory Partners (Nominated Adviser)

T: +44 (0)203 368 3550

Matt Davis/ Adam Dawes




Panmure Gordon (UK) Limited (Broker)

T: +44 (0)207 886 2500

Rupert Dearden/ Freddy Crossley/ Emma Earl




FTI Consulting

T: +44 (0)203 727 1000

Simon Conway/ Ciara Martin


 

 

About Redx Pharma Plc

 

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted therapeutics for the treatment of fibrotic disease, cancer and the emerging area of cancer-associated fibrosis. Redx aims to progress its programmes to clinical proof of concept before evaluating options for further development and potential value creation. The Company expects a number of data points during 2024 including from lead fibrosis product candidate, the selective ROCK2 inhibitor, zelasudil (RXC007), in development for interstitial lung disease and currently undertaking a Phase 2a trial for idiopathic pulmonary fibrosis (IPF). The Company's second fibrosis candidate, RXC008, a GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, is in Phase 1 development and is expected to report healthy volunteer data; and Redx's lead oncology product candidate, the Porcupine inhibitor zamaporvint (RXC004), being developed as a targeted treatment for Wnt-ligand dependent cancers, is expected to report anti-PD-1 combination Phase 2 data, following which Redx will seek a partner for ongoing development.

 

The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by its wholly-owned clinical-stage product candidates and discovery pipeline, but also by its strategic transactions, which includes the sale of pirtobrutinib (RXC005, LOXO-305), the only non-covalent or reversible BTK inhibitor now approved by the US FDA, and transactions with both AstraZeneca and Jazz Pharmaceuticals.

 

To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/.

 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1.

Details of the person discharging managerial responsibilities (PDMR) / person closely associated

a)

Name

Peter Collum

 

2.

Reason for the notification

a)

Position / status

Chief Financial Officer

 

b)

Initial notification / Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Redx Pharma plc

 

b)

LEI

213800HMS4EBXO589Y37

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary Shares of 1 pence each in Redx Pharma plc

 

 

ISIN for Redx Pharma plc Ordinary Shares:

GB00BSNB6S51

 

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Prices(a) and volume(s)

 

Purchase Price per Ordinary Share

Volume



8.5 pence

45,000 Ordinary Shares

 

 

d)

Aggregated information

- Aggregated volume

- Price

 

45,000

 8.5p

e)

Date of the transaction

 26 April 2024

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

1.

Details of the person discharging managerial responsibilities (PDMR) / person closely associated

a)

Name

Peter Collum

 

2.

Reason for the notification

a)

Position / status

Chief Financial Officer

 

b)

Initial notification / Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Redx Pharma plc

 

b)

LEI

213800HMS4EBXO589Y37

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary Shares of 1 pence each in Redx Pharma plc

 

 

ISIN for Redx Pharma plc Ordinary Shares: 

GB00BSNB6S51

 

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Prices(a) and volume(s)

Purchase Price per Ordinary Share

Volume



11.5 pence

50,000 Ordinary Shares

d)

Aggregated information

- Aggregated volume

- Price

 

50,000

11.5p

e)

Date of the transaction

29 April 2024

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

 

1.

Details of the person discharging managerial responsibilities (PDMR) / person closely associated

a)

Name

Claire Solk

 

2.

Reason for the notification

a)

Position / status

General Counsel

 

b)

Initial notification / Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Redx Pharma plc

 

b)

LEI

213800HMS4EBXO589Y37

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary Shares of 1 pence each in Redx Pharma plc

 

 

ISIN for Redx Pharma plc Ordinary Shares:

GB00BSNB6S51

 

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Prices(a) and volume(s)

Purchase Price per Ordinary Share

Volume



11.75 pence

170,204 Ordinary Shares

10.50 pence

1,904 Ordinary shares

d)

Aggregated information

- Aggregated volume

- Price

 

172,108

 11.74p

e)

Date of the transaction

29 April 2024

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHILMMTMTITTAI
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

5 min read